{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:42:30Z","timestamp":1792078950433,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This systematic review explores the relationship between achieving minimal disease activity in psoriasis and the progression of atherosclerosis. It investigates how biologic therapies and other treatments impact atherosclerosis markers, offering insights into therapeutic strategies. A comprehensive search of PubMed, Embase, and Web of Science was conducted from January 1, 2000, to April 1, 2023, using terms such as psoriasis, psoriatic arthritis, atherosclerosis, biologic therapy, vascular stiffness, carotid intima-media thickness (CIMT), and coronary computed tomography angiography (CCTA). Eligible studies were those involving human subjects over 18, written in English, that provided quantitative atherosclerosis markers, including CIMT, CCTA, arterial pulse wave velocity (aPWV), fat attenuation index (FAI), and augmentation index (Aix). From an initial pool of 217 studies, 21 were included, grouped by treatments, including TNF-\u03b1 inhibitors, IL-12\/23 inhibitors, IL-17 inhibitors, DMARDs, phototherapy, and fumaric acid esters. The review found that TNF-\u03b1 inhibitors significantly improved atherosclerosis markers such as CIMT, aPWV, FAI, and C-reactive protein (CRP), with reductions in these markers compared to no treatment, phototherapy, and IL-12\/23 inhibitors. Additionally, IL-17 inhibitors demonstrated similar reductions in FAI compared to TNF-\u03b1 inhibitors but showed a greater effect in reducing non-calcified plaque burden (12% vs. 5% for TNF-\u03b1 inhibitors, p\u2009&lt;\u20090.001) and also decreased CRP levels. Fumaric acid improved cholesterol metabolism (p\u2009&lt;\u20090.04), and TNF-\u03b1 inhibitors enhanced endothelial function (p\u2009&lt;\u20090.01). Mixed results were observed when compared to DMARDs, indicating that patient-specific factors should guide treatment choices. In conclusion, TNF-\u03b1 inhibitors are highly effective in reducing atherosclerosis progression in psoriasis patients, consistently improving vascular health markers like CIMT, aPWV, FAI, and CRP. IL-17 inhibitors also show significant efficacy, particularly in reducing non-calcified plaque burden, making them a valuable alternative to TNF-\u03b1 inhibitors. Fumaric acid\u2019s role in cholesterol metabolism suggests its potential in combination therapies. These findings support integrating TNF-\u03b1 and IL-17 inhibitors into treatment protocols for psoriasis patients with comorbid atherosclerosis, improving cardiovascular outcomes.<\/jats:p>","DOI":"10.1007\/s00403-024-03625-6","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T10:46:50Z","timestamp":1735555610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Psoriasis treatments in the stabilization of atherosclerosis: a systematic review"],"prefix":"10.1007","volume":"317","author":[{"given":"Lixin","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Vukelic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangkyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"12","key":"3625_CR1","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","volume":"141","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ (2005) Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 141(12):1537\u20131541. https:\/\/doi.org\/10.1001\/archderm.141.12.1537","journal-title":"Arch Dermatol"},{"key":"3625_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.2004.032482","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3625_CR3","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/bjd.12490","volume":"169","author":"IM Miller","year":"2013","unstructured":"Miller IM, Skaaby T, Ellervik C, Jemec GB (2013) Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis. Br J Dermatol 169(6):1180\u20131187. https:\/\/doi.org\/10.1111\/bjd.12490","journal-title":"Br J Dermatol"},{"issue":"2","key":"3625_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74(2):326\u2013332. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205675","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3625_CR5","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3899\/jrheum.140882","volume":"41","author":"A Ogdie","year":"2014","unstructured":"Ogdie A, Schwartzman S, Eder L et al (2014) Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol 41(11):2315\u20132322. https:\/\/doi.org\/10.3899\/jrheum.140882","journal-title":"J Rheumatol"},{"issue":"45","key":"3625_CR6","doi-asserted-by":"publisher","first-page":"e31667","DOI":"10.1097\/md.0000000000031667","volume":"101","author":"M Yang","year":"2022","unstructured":"Yang M, Tian S, Lin Z, Fu Z, Li C (2022) Costimulatory and coinhibitory molecules of B7-CD28 family in cardiovascular atherosclerosis: a review. Medicine (Baltimore) 101(45):e31667. https:\/\/doi.org\/10.1097\/md.0000000000031667","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"3625_CR7","doi-asserted-by":"publisher","first-page":"10402","DOI":"10.3390\/ijms221910402","volume":"22","author":"K Wierzbowska-Drabik","year":"2021","unstructured":"Wierzbowska-Drabik K, Lesiak A, Skibi\u0144ska M, Nied\u017awied\u017a M, Kasprzak JD, Narbutt J (2021) Psoriasis and atherosclerosis-skin, joints, and cardiovascular story of two plaques in relation to the treatment with biologics. Int J Mol Sci 22(19):10402. https:\/\/doi.org\/10.3390\/ijms221910402","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3625_CR8","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1161\/atvbaha.114.304108","volume":"34","author":"S Karbach","year":"2014","unstructured":"Karbach S, Croxford AL, Oelze M et al (2014) Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol 34(12):2658\u20132668. https:\/\/doi.org\/10.1161\/atvbaha.114.304108","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"3625_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/art.22530","volume":"57","author":"C Gonzalez-Juanatey","year":"2007","unstructured":"Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA et al (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57(2):287\u2013293. https:\/\/doi.org\/10.1002\/art.22530","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3625_CR10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1365-2133.2010.09992.x","volume":"163","author":"S Coimbra","year":"2010","unstructured":"Coimbra S, Oliveira H, Reis F et al (2010) Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-\u03b1 levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 163(6):1282\u20131290. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09992.x","journal-title":"Br J Dermatol"},{"issue":"10","key":"3625_CR11","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1468-3083.2012.04706.x","volume":"27","author":"YY Chin","year":"2013","unstructured":"Chin YY, Yu HS, Li WC et al (2013) Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. J Eur Acad Dermatol Venereol 27(10):1262\u20131268. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04706.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"3625_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"issue":"12","key":"3625_CR13","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1080\/14712598.2022.2152321","volume":"22","author":"F Sunzini","year":"2022","unstructured":"Sunzini F, D\u2019Antonio A, Fatica M et al (2022) What\u2019s new and what\u2019s next for biological and targeted synthetic treatments in psoriatic arthritis? Expert Opin Biol Ther 22(12):1545\u20131559. https:\/\/doi.org\/10.1080\/14712598.2022.2152321","journal-title":"Expert Opin Biol Ther"},{"issue":"Pt A","key":"3625_CR14","doi-asserted-by":"publisher","first-page":"109341","DOI":"10.1016\/j.intimp.2022.109341","volume":"113","author":"S Parab","year":"2022","unstructured":"Parab S, Doshi G (2022) An update on emerging immunological targets and their inhibitors in the treatment of psoriasis. Int Immunopharmacol 113(Pt A):109341. https:\/\/doi.org\/10.1016\/j.intimp.2022.109341","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"3625_CR15","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamadermatol.2016.1984","volume":"152","author":"KF Hjuler","year":"2016","unstructured":"Hjuler KF, Bottcher M, Vestergaard C, Botker HE, Iversen L, Kragballe K (2016) Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol 152(10):1114\u20131121. https:\/\/doi.org\/10.1001\/jamadermatol.2016.1984","journal-title":"JAMA Dermatol"},{"issue":"9","key":"3625_CR16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","volume":"4","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Oikonomou EK, Dey AK et al (2019) Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. Jama Cardiol 4(9):885\u2013891. https:\/\/doi.org\/10.1001\/jamacardio.2019.2589","journal-title":"Jama Cardiol"},{"issue":"9","key":"3625_CR17","doi-asserted-by":"publisher","first-page":"e011199","DOI":"10.1161\/circimaging.120.011199","volume":"13","author":"H Choi","year":"2020","unstructured":"Choi H, Uceda DE, Dey AK et al (2020) Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study. Circ Cardiovasc Imaging 13(9):e011199. https:\/\/doi.org\/10.1161\/circimaging.120.011199","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"3625_CR18","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1016\/j.jid.2022.05.1085","volume":"142","author":"AR Berg","year":"2022","unstructured":"Berg AR, Hong CG, Svirydava M et al (2022) Association of S100A8\/A9 with lipid-rich necrotic core and treatment with biologic therapy in patients with psoriasis: results from an observational cohort study. J Invest Dermatol 142(11):2909\u20132919. https:\/\/doi.org\/10.1016\/j.jid.2022.05.1085","journal-title":"J Invest Dermatol"},{"issue":"4","key":"3625_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Dey AK, Goyal A et al (2019) Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 115(4):721\u2013728. https:\/\/doi.org\/10.1093\/cvr\/cvz009","journal-title":"Cardiovasc Res"},{"key":"3625_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/jdv.01-13709","volume":"30","author":"KF Hjuler","year":"2016","unstructured":"Hjuler KF, B\u00f8ttcher M, Vestergaard C, B\u00f8tker HE, Kragballe K, Iversen L (2016) Reduced coronary artery disease progression in patients with severe psoriasis treated with biologic agents. J Eur Acad Dermatol Venereol 30:40\u201341. https:\/\/doi.org\/10.1111\/jdv.01-13709","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3625_CR21","first-page":"A12596","volume":"138","author":"YA Elnabawi","year":"2018","unstructured":"Elnabawi YA, Varghese NJ, Sanda GE et al (2018) Immunomodulatory therapy favorably modifies coronary plaque morphology in psoriasis. Circulation 138:A12596","journal-title":"Circulation."},{"issue":"3","key":"3625_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.40366","volume":"70","author":"L Eder","year":"2018","unstructured":"Eder L, Joshi AA, Dey AK et al (2018) Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthrit Rheumatol 70(3):408\u2013416. https:\/\/doi.org\/10.1002\/art.40366","journal-title":"Arthrit Rheumatol"},{"key":"3625_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/eurheartj\/ehp413","volume":"30","author":"K Angel","year":"2009","unstructured":"Angel K, Provan SA, Kvien TK, Atar D (2009) TNF-alpha antagonists improve arterial stiffness in patients with inflammatory arthropathies: results from a controlled study. Eur Heart J 30:297\u2013298. https:\/\/doi.org\/10.1093\/eurheartj\/ehp413","journal-title":"Eur Heart J"},{"issue":"2","key":"3625_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/hypertensionaha.109.143982","volume":"55","author":"K Angel","year":"2010","unstructured":"Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D (2010) Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 55(2):333\u2013338. https:\/\/doi.org\/10.1161\/hypertensionaha.109.143982","journal-title":"Hypertension"},{"issue":"6","key":"3625_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/ajh.2012.12","volume":"25","author":"K Angel","year":"2012","unstructured":"Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D (2012) Effect of 1-Year Anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 25(6):644\u2013650. https:\/\/doi.org\/10.1038\/ajh.2012.12","journal-title":"Am J Hypertens"},{"key":"3625_CR26","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/01.hjh.0000378296.58544.7c","volume":"28","author":"K Angel","year":"2010","unstructured":"Angel K, Provan SA, Fagerhol M, Kvien TK, Atar D (2010) Improvement in aortic stiffness during anti-tumor necrosis factor-alpha therapy in patients with inflammatory arthropathies is associated with reduction in calprotectin. J Hypertens 28:e30","journal-title":"J Hypertens"},{"issue":"1","key":"3625_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.55563\/clinexprheumatol\/3qiqk3","volume":"39","author":"A Ortolan","year":"2021","unstructured":"Ortolan A, Ramonda R, Lorenzin M et al (2021) Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. Clin Exp Rheumatol 39(1):158\u2013161. https:\/\/doi.org\/10.55563\/clinexprheumatol\/3qiqk3","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"3625_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11739-010-0458-6","volume":"5","author":"G Mazzoccoli","year":"2010","unstructured":"Mazzoccoli G, Notarsanto I, de Pinto GD et al (2010) Anti-tumor necrosis factor-\u03b1 therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med 5(6):495\u2013500. https:\/\/doi.org\/10.1007\/s11739-010-0458-6","journal-title":"Intern Emerg Med"},{"issue":"9","key":"3625_CR29","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1111\/jdv.14841","volume":"32","author":"A Martinez-Lopez","year":"2018","unstructured":"Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, Tercedor-Sanchez J, Arias-Santiago S (2018) Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis. J Eur Acad Dermatol Venereol 32(9):1492\u20131498. https:\/\/doi.org\/10.1111\/jdv.14841","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3625_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1161\/atvbaha.110.214585","volume":"31","author":"MND Di Minno","year":"2011","unstructured":"Di Minno MND, Iervolino S, Peluso R, Scarpa R, Di Minno G, Ca RSG (2011) Carotid intima-media thickness in psoriatic arthritis differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 31(3):705\u2013712. https:\/\/doi.org\/10.1161\/atvbaha.110.214585","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"3625_CR31","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1016\/j.jid.2022.09.127","volume":"142","author":"M Aleissa","year":"2022","unstructured":"Aleissa M, Viguier M, Khettab H et al (2022) 117 Longitudinal follow-up study of arterial structure in patients with severe psoriasis and treated with ustekinumab or with tumor necrosis factor alpha inhibitors. J Investig Dermatol 142(12):S200. https:\/\/doi.org\/10.1016\/j.jid.2022.09.127","journal-title":"J Investig Dermatol"},{"issue":"5","key":"3625_CR32","doi-asserted-by":"publisher","first-page":"AB254","DOI":"10.1016\/j.jaad.2016.02.988","volume":"74","author":"G Blasco-Morente","year":"2016","unstructured":"Blasco-Morente G, Masegosa-Casanova S, Montes-Garc\u00eda S et al (2016) Impact of treatment of psoriasis on carotid intima-media thickness. J Am Acad Dermatol 74(5):AB254","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3625_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/jdv.16635","volume":"35","author":"G Holzer","year":"2021","unstructured":"Holzer G, Hoke M, Sabeti-Sandor S et al (2021) Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial. J Eur Acad Dermatol Venereol 35(2):441\u2013449. https:\/\/doi.org\/10.1111\/jdv.16635","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3625_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1756-185X.2010.01505.x","volume":"13","author":"LS Tam","year":"2010","unstructured":"Tam LS, Li EK, Shang Q et al (2010) TNF-alpha blockade is associated with sustained reduction of carotid intima-media thickness for patients with active psoriatic arthritis\u2014A 2 year study. Int J Rheum Dis 13:159. https:\/\/doi.org\/10.1111\/j.1756-185X.2010.01505.x","journal-title":"Int J Rheum Dis"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03625-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:03:58Z","timestamp":1735556638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03625-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03625-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"159"}}